Do not stop or change your medication without speaking to a pharmacist or healthcare professional.
Permanently Discontinued

AXERT 6.25MG

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is AXERT 6.25MG discontinued in Canada?

Yes. The manufacturer has reported to Health Canada that AXERT 6.25MG has been permanently discontinued (last updated October 28, 2017). It is not expected to come back, so talk to your pharmacist or doctor about an alternative.

Why is AXERT 6.25MG not available?

The reason the manufacturer reported: Business reasons.

Can I still get this?Possibly — same-ingredient product records found
StatusPermanently Discontinued
Same-ingredient products on file5 products
Affected strength6.25MG
Last updated2017-10-28

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Closest Matches

AG-ALMOTRIPTAN

ANGITA PHARMA INC.

6.25MG · DIN 02570289

Same strengthSame dosage formSame routeNo current shortage

Other Products

SANDOZ ALMOTRIPTAN

SANDOZ CANADA INCORPORATED

12.5MG · DIN 02405334

Different strengthSame dosage formSame routeNo current shortage

JAMP ALMOTRIPTAN

JAMP PHARMA CORPORATION

12.5MG · DIN 02556030

Different strengthSame dosage formSame routeNo current shortage

ALMOTRIPTAN

SANIS HEALTH INC

12.5MG · DIN 02466821

Different strengthSame dosage formSame routeNo current shortage

PMS-ALMOTRIPTAN

PHARMASCIENCE INC

12.5MG · DIN 02441411

Different strengthSame dosage formSame routeNo current shortage

What this means

Does this mean I need to switch medications right away?

Not necessarily right away, but this product will not be returning to the market.

What should I do?

Talk to your pharmacist or prescriber about your options well before your current supply runs out.

DIN

02248128

Strength

6.25MG

Dosage Form

TABLET

Route

ORAL

Active Ingredient

ALMOTRIPTAN

See all ALMOTRIPTAN products →

Shortage History

Other Products from MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.